SPBC18H10.20c Antibody

What is SPBC18H10.20c and why would researchers need antibodies against it?

SPBC18H10.20c, named Arn1 (arrestin 1) or Any1, is a protein in Schizosaccharomyces pombe that exhibits high homology to ART1, a member of the arrestin-related trafficking adaptor (ART) family in Saccharomyces cerevisiae. It contains a conserved arrestin motif within an arrestin fold domain, a putative ubiquitination site, and two PY motifs . The protein plays a crucial role in regulating amino acid uptake through controlling endocytosis of amino acid transporters, particularly Cat1. Antibodies against this protein are essential for studying its expression, localization, interactions, and post-translational modifications, allowing researchers to understand its role in cellular processes and potentially in disease models where arrestin functions are implicated.

How can I validate the specificity of a SPBC18H10.20c antibody?

To validate the specificity of a SPBC18H10.20c antibody, implement the following methodological approach:

• Genetic controls: Compare antibody signals between wild-type and arn1Δ deletion strains in Western blots and immunofluorescence. A specific antibody will show signal in wild-type but not in deletion strains.

• Overexpression validation: Test the antibody on samples overexpressing tagged Arn1 (such as Arn1-3HA as described in the literature) to confirm increased signal intensity .

• Epitope competition assay: Pre-incubate the antibody with purified recombinant SPBC18H10.20c protein before application to samples. Specific binding should be blocked.

• Cross-reactivity assessment: Test against the homologous protein Arn2 (SPAC1F12.05), which shares 38% identity and 57% similarity to Arn1 , to ensure antibody specificity between these related proteins.

• Mass spectrometry confirmation: Perform immunoprecipitation followed by mass spectrometry analysis to confirm that the precipitated protein is indeed SPBC18H10.20c.

What expression systems are recommended for producing recombinant SPBC18H10.20c for antibody generation?

For generating high-quality antibodies against SPBC18H10.20c, consider these expression systems with their respective advantages:

Bacterial expression systems (E. coli):

• Simplest and most cost-effective approach

• Best suited for producing the arrestin fold domain alone (amino acids containing the conserved arrestin motif)

• Consider using strains optimized for eukaryotic protein expression (Rosetta, BL21-CodonPlus)

• May require optimization of solubility using fusion tags (MBP, SUMO, or GST)

Yeast expression systems:

• S. cerevisiae or P. pastoris offer proper folding and some post-translational modifications

• More likely to produce functional protein with native conformation

• Particularly useful for antibodies intended for conformational epitopes

• Can be expressed with the same tags (3HA, Myc) used successfully in the literature

Baculovirus/insect cell system:

• Optimal for producing full-length protein with most post-translational modifications

• Useful if targeting ubiquitinated forms or other modifications

• Higher cost but better quality protein for complex structural epitopes

Cell-free systems:

• Rapid production for initial screening

• Useful for producing potentially toxic proteins

A recommended approach is to produce both full-length protein and specific domains (particularly the arrestin domain) to generate and purify domain-specific antibodies.

What are the critical post-translational modifications of Arn1/Any1 that antibodies might need to detect?

Based on the literature, several key post-translational modifications of SPBC18H10.20c/Arn1 are critical for functional studies:

• Ubiquitination: Arn1 is ubiquitinated by the Pub1 ubiquitin ligase at lysine 263 (K263), which is essential for its function in regulating Cat1 endocytosis . Developing antibodies that specifically recognize ubiquitinated Arn1 would be valuable for studying this regulatory mechanism.

• Unknown modification: Research has identified an additional modification of Arn1 that results in a middle band on Western blots. This modification is not affected by PY motif mutations or pub1 deletion but is abolished by the K263R substitution. Interestingly, this modification was not detected with anti-ubiquitin antibodies and was determined not to be SUMOylation . Antibodies specifically recognizing this modification would help characterize this novel regulatory mechanism.

• Potential phosphorylation: While not explicitly reported in the provided search results, arrestin family proteins are often regulated by phosphorylation. Residue-specific phospho-antibodies might be useful for studying regulatory mechanisms.

• PY motif interactions: Although not a modification per se, the PY motifs in Arn1 interact with the WW domains of the Pub1 E3 ligase. Antibodies that can recognize the conformation of free versus Pub1-bound PY motifs could help study this interaction.

A panel of modification-specific antibodies would be particularly valuable for dissecting the complex regulation of this protein.

How can antibodies be used to study the role of SPBC18H10.20c in the context of the Tsc1-Tsc2 complex pathway?

Antibodies against SPBC18H10.20c can be instrumental in investigating its functional relationship with the Tsc1-Tsc2 complex pathway through these methodological approaches:

• Co-immunoprecipitation studies: Use anti-Arn1 antibodies to immunoprecipitate Arn1 and probe for Tsc1/Tsc2 components to identify direct or indirect interactions within protein complexes. Reciprocally, immunoprecipitate Tsc2 and probe for Arn1 to validate interactions.

• Proximity labeling assays: Combine anti-Arn1 antibodies with BioID or APEX2 proximity labeling to identify proteins in close proximity to Arn1 in wild-type versus tsc2Δ backgrounds.

• Localization studies: Perform immunofluorescence with anti-Arn1 antibodies in wild-type and tsc2Δ cells to determine if Tsc2 affects Arn1 subcellular localization. The literature shows that deletion of arn1+ suppresses the defect of amino acid uptake and the aberrant Cat1 localization in tsc2Δ cells , suggesting functional interaction.

• Signaling pathway analysis: Use phospho-specific antibodies against components of the Tsc1-Tsc2 signaling pathway in wild-type versus arn1Δ cells to determine if Arn1 influences Tsc1-Tsc2 signaling.

• Temporal dynamics: Employ antibodies in time-course experiments after amino acid starvation/refeeding to track the dynamics of Arn1 in relation to Tsc1-Tsc2 complex activity.

These approaches would help elucidate how Arn1 functions in the amino acid sensing pathways involving the Tsc1-Tsc2 complex, potentially revealing new regulatory mechanisms.

What controls should be included when using SPBC18H10.20c antibodies to study the endocytosis of amino acid transporters?

When using SPBC18H10.20c antibodies to study amino acid transporter endocytosis, the following controls are essential for robust experimental design:

Genetic controls:

• arn1Δ strain: Primary negative control that should show altered Cat1 localization and endocytosis patterns

• Strains with K263R mutation: To study ubiquitination-independent functions

• pub1Δ strain: To investigate the role of Pub1-mediated ubiquitination in the process

• tsc2Δ strain: As deletion of arn1+ suppresses the aberrant Cat1 localization in tsc2Δ

Experimental controls:

• Time-course analysis after endocytosis induction (e.g., canavanine treatment)

• Membrane fractionation to distinguish plasma membrane from endosomal populations

• Co-localization with established endocytic markers (e.g., FM4-64)

• Parallel tracking of known Arn1 targets (particularly Cat1 amino acid transporter)

• Treatment with endocytosis inhibitors to confirm the observed effects are endocytosis-dependent

Antibody controls:

• Pre-immune serum controls for polyclonal antibodies

• IgG isotype controls for monoclonal antibodies

• Peptide competition assays to demonstrate binding specificity

• Secondary antibody-only controls to exclude non-specific binding

Additional methodological considerations:

• Use both fixed and live-cell imaging approaches to capture dynamic processes

• Employ super-resolution microscopy to distinguish closely associated proteins

• Quantify co-localization with endocytic machinery components

• Include canavanine sensitivity/resistance assays as functional readouts of proper Cat1 regulation

How can SPBC18H10.20c antibodies be optimized for detecting protein-protein interactions through co-immunoprecipitation?

Optimizing SPBC18H10.20c antibodies for co-immunoprecipitation (co-IP) studies requires addressing several key considerations:

Antibody selection and preparation:

• Epitope location: Select antibodies targeting regions outside known protein-protein interaction domains, particularly avoiding the arrestin domain, PY motifs, and K263 ubiquitination site .

• Antibody affinity purification: Affinity-purify antibodies against the specific epitope to reduce background.

• Cross-linking strategies: Consider cross-linking antibodies to beads (Protein A/G) to prevent antibody contamination in mass spectrometry analysis.

Buffer optimization:

• Lysis conditions: Use the validated buffer conditions described in the literature - Buffer A (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 0.2% NP-40, and protease inhibitors) for standard interactions .

• Stringency adjustment: Modify salt concentration and detergent type/concentration based on the interaction strength being studied.

• Special considerations: For ubiquitinated forms, include deubiquitinase inhibitors (N-ethylmaleimide) and use urea buffer as described in the methodology section of referenced research .

Experimental protocol refinements:

• Pre-clearing step: Include pre-clearing with Protein G-Sepharose to reduce non-specific binding.

• Incubation conditions: Optimize antibody amount, incubation time (2-4 hours as used in the literature), and temperature (4°C) .

• Washing stringency: Balance between preserving specific interactions and removing non-specific binding.

• Elution strategy: Consider specific elution with competing peptides when possible (as demonstrated with myc-peptides in the referenced studies) .

Validation approaches:

• Reciprocal co-IP: Confirm interactions by immunoprecipitating with antibodies against the suspected interacting partner.

• Known interaction controls: Include the established Arn1-Pub1 interaction as a positive control .

• Negative controls: Use arn1Δ strains and IgG isotype controls.

These optimizations will enhance the specificity and sensitivity of co-IP experiments using SPBC18H10.20c antibodies.

Can antibodies be developed to specifically recognize different functional states of Arn1/Any1?

Developing antibodies that recognize specific functional states of Arn1/Any1 is challenging but feasible with the following approaches:

1. Conformation-specific antibodies:

• Generate antibodies against peptides representing distinct conformational states (active vs. inactive)

• Use phage display technology to select antibodies that bind only to specific protein conformations

• Employ structural modeling to identify regions that undergo conformational changes during activation

2. Modification-state specific antibodies:

• Develop antibodies that specifically recognize ubiquitinated K263, which is critical for Arn1 function

• Generate antibodies against the middle-band modification of unknown nature observed in research studies

• Produce phospho-specific antibodies against predicted regulatory phosphorylation sites

3. Interaction-dependent epitope antibodies:

• Create antibodies that recognize epitopes only accessible when Arn1 is not bound to Pub1

• Develop antibodies against the PY motifs that are blocked when interacting with WW domains of Pub1

4. Subcellular localization-specific antibodies:

• Generate antibodies that distinguish between membrane-associated and cytosolic pools of Arn1

• Use native conformation-preserving immunization strategies with intact protein complexes

5. Advanced antibody engineering approaches:

• Develop bi-specific scFv antibodies that simultaneously recognize Arn1 and its interaction partners

• Create proximity-dependent antibodies using split-protein complementation principles

Validation strategies:

• Test antibodies in wild-type cells versus cells expressing Arn1 mutants locked in specific states

• Use structural biology techniques (X-ray crystallography, cryo-EM) to confirm epitope exposure in different states

• Perform cellular assays correlating antibody recognition with functional readouts like canavanine resistance

Such state-specific antibodies would be powerful tools for dissecting the dynamics of Arn1 function in regulating amino acid transport.

What is the optimal Western blot protocol for detecting SPBC18H10.20c/Arn1 and its modified forms?

Based on the published research, the following optimized Western blot protocol is recommended for detecting SPBC18H10.20c/Arn1 and its various modified forms:

Sample preparation:

• Extract proteins using either:

  • Standard lysis buffer (Buffer A: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 0.2% NP-40) with protease inhibitors for general detection

  • Urea buffer (50 mM Tris-HCl pH 7.5, 8 M urea, 50 mM NaCl, 1 mM EDTA, 1% Triton X-100) for detecting ubiquitinated forms

• Include specific inhibitors:

  • Protease inhibitors (PMSF, leupeptin, pepstatin)

  • Deubiquitinase inhibitors (N-ethylmaleimide, PR-619) for preserving ubiquitinated forms

  • Phosphatase inhibitors (sodium orthovanadate, sodium fluoride) if studying phosphorylation

Gel electrophoresis:

• Use 8-10% polyacrylamide gels to properly resolve the multiple forms of Arn1 (approximately 53 kDa plus modifications)

• Load appropriate controls: arn1Δ lysate, K263R mutant (ubiquitination-deficient), and PY motif mutants

• Include molecular weight markers covering 40-100 kDa range

Transfer and detection:

• Transfer to PVDF membrane (recommended over nitrocellulose for detecting multiple modifications)

• Blocking: 5% non-fat dry milk in TBS-T (1 hour at room temperature)

• Primary antibody incubation:

  • Anti-Arn1 antibody (overnight at 4°C)

  • For detecting ubiquitinated forms, parallel blots with anti-ubiquitin antibodies

• Extensive washing with TBS-T (4-5 times, 5-10 minutes each)

• Secondary antibody: HRP-conjugated or fluorescent secondary antibodies (1-2 hours at room temperature)

• Detection system: Enhanced chemiluminescence for highest sensitivity to detect modified forms

Special considerations:

• To visualize all forms simultaneously, use gradient gels (4-15%)

• For detecting the middle band of unknown modification, compare with K263R mutant samples

• For ubiquitinated forms, consider parallel Ni-NTA pull-down of His-tagged ubiquitin as described in the literature

This protocol has been demonstrated to successfully detect multiple forms of Arn1, including unmodified, ubiquitinated, and the middle band of unknown modification.

How can immunofluorescence protocols be optimized for studying SPBC18H10.20c localization in S. pombe?

Optimizing immunofluorescence protocols for SPBC18H10.20c localization in S. pombe requires addressing the unique challenges of fission yeast cell biology:

Cell fixation and permeabilization:

• Primary fixation method: Formaldehyde fixation (4% for 30 minutes) preserves most protein-protein interactions

• Alternative fixation: Methanol fixation (-20°C for 6 minutes) may better preserve certain epitopes and membrane structures

• Cell wall digestion: Use Zymolyase (0.5 mg/ml, 30 minutes at 37°C) for controlled cell wall digestion

• Permeabilization: Gentle permeabilization with 0.1% Triton X-100 for 5 minutes to maintain membrane structures

Antibody incubation:

• Blocking: Extended blocking (2 hours) with 5% BSA and 1% normal serum from secondary antibody host species

• Primary antibody: Incubate at 4°C overnight in humidity chamber with optimized antibody dilution

• Co-localization markers: Include antibodies against compartment markers such as:

  • Endocytic vesicles: Anti-Ypt7 (late endosomes)

  • Plasma membrane: Fluorescent wheat germ agglutinin

  • Endoplasmic reticulum: Anti-BiP

• Secondary antibodies: Highly cross-absorbed secondary antibodies to reduce background in the small yeast cell volume

Mounting and imaging:

• Anti-fade mounting: Use mounting medium with anti-fade agents and DAPI for nuclear counterstaining

• Z-stack acquisition: Collect 0.2-0.3 μm z-sections through the entire cell

• Deconvolution: Apply appropriate deconvolution algorithms for the small yeast cell size

• Super-resolution techniques: Consider structured illumination microscopy (SIM) or STED for resolving close membrane associations

Critical controls:

• Genetic controls: Include arn1Δ cells as negative controls

• Epitope competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Secondary antibody-only: Control for non-specific binding

• Co-localization validation: Include cells expressing Arn1-GFP fusion proteins for validation

Special considerations for S. pombe:

• Cell cycle staging: Use DAPI staining patterns to classify cells by cell cycle stage

• Septation monitoring: Include calcofluor white staining to identify dividing cells

• Cell shape mutants: Consider how cell morphology affects protein localization interpretation

These optimizations will help overcome the challenges of immunofluorescence in the small fission yeast cells while providing reliable localization data for SPBC18H10.20c/Arn1.

What approaches can be used to develop antibodies that distinguish between SPBC18H10.20c/Arn1 and its homolog Arn2?

Developing antibodies that specifically distinguish between Arn1 and its homolog Arn2 (which share 38% identity and 57% similarity ) requires strategic approaches targeting their differences:

Epitope selection strategies:

• Sequence divergence analysis: Perform detailed sequence alignment between Arn1 and Arn2 to identify regions with low homology

• Structural prediction: Use structural modeling to identify surface-exposed regions unique to each protein

• Functional domain targeting: Focus on regions outside the conserved arrestin fold domain, which is likely similar between the proteins

• Post-translational modification sites: Target regions containing unique modification sites

Recommended peptide antigens:

• N-terminal and C-terminal peptides: These regions often have higher sequence divergence

• Linker regions: Target sequences connecting conserved domains

• Custom peptide design: Synthesize peptides from uniquely modified regions (e.g., around K263 ubiquitination site in Arn1 )

Antibody production approaches:

• Subtractive immunization strategy:

  • Pre-immunize with the homologous protein (Arn2)

  • Tolerize the immune system to common epitopes

  • Then immunize with the target protein (Arn1)

  • This enriches for antibodies against unique epitopes

• Phage display selection with negative selection:

  • Screen antibody libraries against Arn1

  • Counter-select against Arn2 to remove cross-reactive antibodies

  • Isolate clones binding only to Arn1

• Monoclonal antibody screening strategy:

  • Screen hybridoma clones against both Arn1 and Arn2

  • Select clones showing differential binding

Validation procedures:

• Cross-reactivity testing: Test all antibodies against both purified recombinant Arn1 and Arn2

• Genetic validation: Test antibodies on wild-type, arn1Δ, arn2Δ, and arn1Δarn2Δ double mutant strains

• Epitope mapping: Confirm the exact binding site to ensure it aligns with the intended unique region

• Western blot validation: Confirm distinct band patterns and molecular weights

• Immunoprecipitation specificity: Verify that the antibody pulls down only the intended target

These approaches will maximize the likelihood of generating truly specific antibodies that can distinguish between these homologous proteins.

How can SPBC18H10.20c antibodies be used to study protein dynamics during nitrogen starvation and quiescence?

SPBC18H10.20c/Arn1 antibodies can be powerful tools for studying protein dynamics during nitrogen starvation and quiescence, particularly considering the role of HIRA (a related chromatin regulator) in nitrogen-starvation induced quiescence in S. pombe . The following methodological approaches are recommended:

Time-course analysis protocols:

• Sequential sampling: Collect cells at defined intervals before, during, and after nitrogen starvation

• Subcellular fractionation: Separate membrane, cytosolic, and nuclear fractions at each timepoint

• Western blot analysis: Track changes in Arn1 abundance, localization, and modification states

• Parallel tracking: Monitor Cat1 transporter dynamics simultaneously to correlate with Arn1 changes

Immunofluorescence applications:

• Co-localization studies: Track changes in Arn1 localization relative to endocytic markers during starvation

• Quantitative imaging: Measure the plasma membrane to cytoplasmic ratio of Arn1 and Cat1 over time

• FRAP analysis: Combine with GFP-tagged proteins to assess mobility changes during starvation

• Super-resolution microscopy: Monitor nanoscale changes in protein distribution patterns

Protein modification analysis:

• Ubiquitination dynamics: Use anti-ubiquitin co-immunoprecipitation to track changes in Arn1 ubiquitination status during starvation

• Phosphorylation mapping: Apply phospho-specific antibodies to identify regulatory phosphorylation events

• Modification-specific antibodies: Apply antibodies specific to the unexplained middle band modification

Protein-protein interaction studies:

• Co-immunoprecipitation time course: Track changes in Arn1-Pub1 interaction during starvation

• Proximity labeling: Apply BioID or APEX2 fusions with Arn1 to identify starvation-specific interaction partners

• Cross-linking mass spectrometry: Apply protein cross-linking at different starvation timepoints

Functional correlation methods:

• Gene expression correlation: Combine with analysis of MBF-dependent gene expression changes known to be regulated during quiescence exit

• Genetic interaction studies: Compare wild-type to hip1Δ (HIRA-deficient) cells to connect Arn1 function to HIRA-regulated quiescence pathways

• Canavanine sensitivity assays: Correlate functional changes in amino acid uptake with Arn1 dynamics

These approaches would provide comprehensive insights into how Arn1 function is regulated during nutritional stress and quiescence, potentially revealing new connections to chromatin regulation pathways involved in these processes.

What considerations are important when generating scFv antibodies against SPBC18H10.20c for live-cell imaging?

When generating single-chain fragment variable (scFv) antibodies against SPBC18H10.20c for live-cell imaging, several critical considerations must be addressed:

Design and production considerations:

• Epitope selection: Target extracellular or surface-exposed domains if studying membrane-associated Arn1, or ensure cell-penetrating capability for cytoplasmic epitopes

• Framework selection: Choose framework regions with demonstrated stability in the reducing cytoplasmic environment

• Expression optimization: Codon-optimize the scFv sequence for S. pombe expression

• Fusion reporter selection: Consider monomeric fluorescent proteins (mNeonGreen, mScarlet) that minimize oligomerization

• Linker design: Implement flexible linkers (GGGGS)n between VH and VL domains to ensure proper folding

Functional validation approaches:

• Binding specificity: Validate against recombinant protein and in arn1Δ strains

• Antigen binding kinetics: Determine affinity constants, aiming for Kd values in the 1-10 nM range for specific detection

• Expression toxicity assessment: Ensure the scFv expression doesn't disrupt normal cellular functions

• Competition assays: Verify the scFv doesn't interfere with Arn1's interaction with binding partners like Pub1

Live-cell imaging optimization:

• Expression level tuning: Use regulatable promoters (nmt1 series) to optimize signal-to-noise ratio

• Photobleaching mitigation: Include antioxidants in imaging media and minimize light exposure

• Cell health monitoring: Track growth rates and morphology to ensure the scFv doesn't disrupt function

• Advanced imaging approaches:

  • FRET-based systems to study protein-protein interactions

  • Split-GFP complementation to visualize specific interaction events

  • Photoswitchable fluorophores for pulse-chase experiments

Technical advantages of scFv for SPBC18H10.20c studies:

• Small size: At ~25 kDa, scFvs minimally interfere with target protein function compared to full IgGs

• Versatility: Can be expressed as intrabodies or displayed on phage for selection

• Genetic fusion capability: Can be directly fused to fluorescent proteins or enzymatic reporters

• Single-component system: Avoids the need for secondary detection reagents

Potential limitations to address:

• Stability concerns: Engineer disulfide bonds or use stable frameworks to enhance cytoplasmic stability

• Expression levels: Balance between sufficient signal and minimal interference with endogenous processes

• Background fluorescence: Implement strategies to reduce free fluorescent protein signal

• Functional interference: Verify the scFv doesn't block key functional sites on Arn1

These considerations will help develop effective scFv-based imaging tools for studying SPBC18H10.20c dynamics in living cells.